An open-label study examining the effect of pharmacological treatment on mannitol- and exercise-induced airway hyperresponsiveness in asthmatic children and adolescents with exercise-induced bronchoconstriction

BMC Pediatr. 2014 Aug 2:14:196. doi: 10.1186/1471-2431-14-196.

Abstract

Background: Mannitol- and exercise bronchial provocation tests are both used to diagnose exercise-induced bronchoconstriction. The study aim was to compare the short-term treatment response to budesonide and montelukast on airway hyperresponsiveness to mannitol challenge test and to exercise challenge test in children and adolescents with exercise-induced bronchoconstriction.

Methods: Patients were recruited from a paediatric asthma rehabilitation clinic located in the Swiss Alps. Individuals with exercise-induced bronchoconstriction and a positive result in the exercise challenge test underwent mannitol challenge test on day 0. All subjects then received a treatment with 400 μg budesonide and bronchodilators as needed for 7 days, after which exercise- and mannitol-challenge tests were repeated (day 7). Montelukast was then added to the previous treatment and both tests were repeated again after 7 days (day 14).

Results: Of 26 children and adolescents with exercise-induced bronchoconstriction, 14 had a positive exercise challenge test at baseline and were included in the intervention study. Seven of 14 (50%) also had a positive mannitol challenge test. There was a strong correlation between airway responsiveness to exercise and to mannitol at baseline (r = 0.560, p = 0.037). Treatment with budesonide and montelukast decreased airway hyperresponsiveness to exercise challenge test and to a lesser degree to mannitol challenge test. The fall in forced expiratory volume in one second during exercise challenge test was 21.7% on day 0 compared to 6.7% on day 14 (p = 0.001) and the mannitol challenge test dose response ratio was 0.036%/mg on day 0 compared to 0.013%/mg on day 14 (p = 0.067).

Conclusion: Short-term treatment with an inhaled corticosteroid and an additional leukotriene receptor antagonist in children and adolescents with exercise-induced bronchoconstriction decreases airway hyperresponsiveness to exercise and to mannitol.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetates / pharmacology
  • Acetates / therapeutic use*
  • Administration, Inhalation
  • Adolescent
  • Anti-Asthmatic Agents / pharmacology
  • Anti-Asthmatic Agents / therapeutic use*
  • Asthma, Exercise-Induced / chemically induced
  • Asthma, Exercise-Induced / drug therapy*
  • Asthma, Exercise-Induced / etiology
  • Bronchial Provocation Tests / methods
  • Bronchoconstrictor Agents / administration & dosage
  • Bronchodilator Agents / pharmacology
  • Bronchodilator Agents / therapeutic use
  • Budesonide / pharmacology
  • Budesonide / therapeutic use*
  • Child
  • Cyclopropanes
  • Drug Administration Schedule
  • Exercise Test
  • Female
  • Forced Expiratory Volume / drug effects
  • Humans
  • Male
  • Mannitol / administration & dosage
  • Quinolines / pharmacology
  • Quinolines / therapeutic use*
  • Sulfides
  • Treatment Outcome
  • Young Adult

Substances

  • Acetates
  • Anti-Asthmatic Agents
  • Bronchoconstrictor Agents
  • Bronchodilator Agents
  • Cyclopropanes
  • Quinolines
  • Sulfides
  • Mannitol
  • Budesonide
  • montelukast